A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest oncology group study S0312

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 453-459

  Van Veldhuizen, Peter J ^a   Hussey, Michael ^b   Lara Jr , Primo N ^c   MacK, Philip C ^c   Gandour Edwards, Regina ^c   Clark, Joseph I ^d   Lange, Marianne K ^e   Crawford, David E ^f  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemotherapy; Gemcitabine; MTOR; PTEN; Renal cell carcinoma

Indexed keywords

CAPECITABINE; DEXAMETHASONE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; ONDANSETRON; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PYRIDOXINE; THYMIDYLATE SYNTHASE; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEARTBURN; HEMOLYSIS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; INSOMNIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PROGNOSIS; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PTEN PHOSPHOHYDROLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 70350640904     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181925176     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Chow W, Devesa S, Warren J, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
3. Lipworth L, Tarone R, McLaughlin J. The epidemiology of renal cell carcinoma. J Urol. 2006;176:2353-2358.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma. New Engl J Med. 1998;338:1272.
5. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997;3:S70-S72.
6. Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006;107:2254-2261.
7. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
8. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004-7014.
9. Park JY, Lin PY, Weiss RH. Targeting the PI3K-Akt Pathway in kidney cancer. Expert Rev Anticancer Ther. 2007;7:863-870.
10. Patel PH, Chadalavada RS, Chaganti RS, et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215-7220.
11. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601-5608.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
13. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:4669-4670.
14. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
15. Wenzel C, Locker GJ, Schmidinger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis. 2002;39:48-54.
16. Wenzel C, Locker GJ, Bartsch R, et al. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs. 2003;14:779-784.
17. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993;4:331-332.
18. De Mulder PH, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol. 1996; 37:491-495.
19. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
20. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer. 2005;103:553-558.
21. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer. 2004;91:1763-1768.
22. Tannir NM, Jonasch E, McMichael C, et al. A phase II trial of gemcitabine plus capecitabine (GX) in patients with metastatic renal cell cancer (mRCC) previously treated with immunotherapy. J Clin Oncol, ASCO Annu Meet Proc. 2005:4598.
23. Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006;107:1273-1279.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
25. Simon P. Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics. 2003;19:1439-1440.
26. Gandour-Edwards R, Mack PC, et al. Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2004;7:321-326.
27. Lara PN Jr, Gandara DR, Longmate J, et al; for the a phase II California Cancer Consortium Trial. Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer. Cancer Chemother Pharmacol. 2001;48:22-28.
28. Ryan CW, Goldman B, Lara PN, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296-3301
29. Salgado J, Zabalegui N, Gil C, et al. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep. 2007;17: 325-328.
30. Mizutani Y, Wada H, Yoshida O, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res. 2003;9:1453-1460. (Pubitemid 36418401)
31. Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. Ann Oncol. 2006;17(suppl 5):v13-v16.
32. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18: 504-509.
33. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267.
34. Horiguchi A, Oya M, Uchida A, et al. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol. 2003;169: 710-713.
35. Shin Lee J, Seok Kim H, Bok Kim Y, et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84:166-172.
36. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall lung cancer. N Engl J Med. 2006;355:2542-2550.
37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluoruracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
38. Blaszkowsky LS, Kulke KH, Ryan DP, et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. J Clin Oncol, ASCO Annual Meeting Proceedings. 2005; 23:Abstract 4099.